Abstract: Disclosed is a leg positioner apparatus to secure placement of a leg in total hip arthroplasty procedures. The leg positioner apparatus can attach to a standard operating table and helps in positioning the operative leg for femoral preparation. The leg positioner apparatus includes a post assembly mounted to an attachment bracket. The attachment bracket can be attached to the operating table. The operative leg can rest on the post assembly during the surgical procedure.

Abstract: Methods and apparatus are described in which IF content is generated at an RF receiver without off-chip MEMS, a local oscillator, or a phase-locked loop, and using a transmitter that transmits a single RF tone.

Abstract: Methods for treating tissue with irreversible electroporation and immunotherapy are described. The methods include placing a probe in tissue within a human body, wherein the probe has at least a first electrode, applying a plurality of electrical pulses through the first electrode and a second electrode, causing irreversible electroporation (IRE) of the tissue within a target ablation zone, and administering one or more exogenous agents into the tissue within the target ablation zone or to the human, thereby stimulating or otherwise modulating an immune system response within the body.

Abstract: Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.

Abstract: A method and apparatus for evaluating the chemical composition of airborne particles by sequentially collecting and analyzing airborne particles in-situ. The method includes: collecting particles; enlarging the particles through water condensation; accelerating the enlarged particles onto a surface to collect enlarged particles; and analyzing the enlarged particles by: isolating the surface; passing a carrier gas over the surface; heating the surface to thermally desorb collected particles into the carrier gas; transporting this evolved vapor into detectors; and assaying the evolved vapor as a function of a desorption temperature. The apparatus includes: a sample flow inlet; a condensational growth tube; a collection and thermal desorption (CTD) cell; a carrier gas source; a heater coupled to the CTD; one or more gas detectors; and a controller configured to operate valves, the heater, the growth tube, and the CTD cell in at least an in-situ sequential collection mode and analysis mode.

Abstract: A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.

Abstract: An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

Abstract: Method, system and computer program product for providing real time detection of analyte sensor sensitivity decline is continuous glucose monitoring systems are provided.

Abstract: Inflammatory cell recruitment to local sites of tissue injury and/or infection is controlled by many signaling processes influencing cell-to-cell interactions between vascular endothelial cells (EC) in post-capillary venules and circulating leukocytes. Here we report that the ATP-release channel Pannexin1 (Panx1) opens downstream of EC activation by tumor necrosis factor ? (TNF?). This process involves activation of Type 1 TNF receptors, recruitment of Src Family Kinases (SFK), and SFK-dependent phosphorylation of Panx1. We report a previously unidentified role for Panx1 channels in promoting leukocyte adhesion and emigration through the venous wall during acute systemic inflammation. The present application further discloses that Panx IL2 peptide consisting of amino acid sequence KYPIVEQYLKYGRKKQRR (SEQ ID NO:3) or 10Panx1 peptide consisting of amino acid sequence WRQAAFVDSY (SEQ ID NO:8) are inhibitors of leukocyte adhesion.

Abstract: A lattice structure includes multiple identical unit cells formed from joined plates. In the lattice structure, some of the plates are rectangular plates, some of the plates are triangular plates, and some of the plates are trapezoidal plates. Further, any two of the joined rectangular plates have corresponding surface normals perpendicular to each other and at least two edges of each one of the triangular plates are joined to one of a surface or an edge of one of the plurality of joined plates. Further, at least three edges of each one of the trapezoidal plates are joined to one of a surface or an edge of one of the plurality of joined plates, and any one of a plurality of surface normals for the triangular plates and the trapezoidal plates are nonparallel to any one of a plurality of surface normals of rectangular plates.

Abstract: The disclosure provides compounds of Formula (I-A) and (I-B) and the pharmaceutically acceptable salts thereof. The variables, R, R2, R3, X1, X2, X3, Y1, Y, and Z are defined herein. Certain compounds of Formula (I-A) and (I-B) act as selective mitochondrial protonophore uncouplers that do not affect plasma membrane potential. These compounds are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH), Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, the compounds are useful for increasing lifespan. Compounds and salts of Formulae (I-A) and (I-B) are also useful for regulating glucose homeostasis or insulin action in a patient.

Abstract: A vaccine composition for intranasal administration includes a Bordetella pertussis antigen, and an effective adjuvant amount of a high molecular weight glucose polymer. The high molecular weight glucose polymer may be a beta-glucan. The Bordetella pertussis antigen may be an extracellular toxin, an adhesion protein, an outer membrane protein, a receptor protein, a fragment thereof, or a mixture thereof.

Abstract: Aspects of the present disclosure include methods for treating at least one of depression, neurodegenerative disease, multiple sclerosis, Parkinson's disease, spinocerebellar degeneration, Friedreich ataxia, ataxia-telangiectasia, progressive supranuclear palsy, Huntington's disease, striatonigral degeneration, olivopontocerebellar atrophy, Shy-Drager syndrome, schizophrenia, schizoaffective disorder, manic-depression (bipolar) disorder, disturbed or abnormal circadian entrainment, childhood Alice in Wonderland syndrome, childhood acute cerebellar ataxia, and Alzheimer's disease. In some instances, methods include treating an addiction to a drug, such as alcohol addiction, cocaine addiction or amphetamine addiction.

Abstract: In various aspects, reinforced composite filaments, methods of making reinforced composite filaments, and methods of producing reinforced composite filament are all provided herein. The reinforced composite filaments can include a thermoplastic polymer matrix having dispersed therein reinforcing fibers composed of a thermotropic liquid crystalline polymer. In some aspects, the thermoplastic polymer matrix is chosen such that a processing temperature for the thermoplastic polymer matrix is below a melting temperature of the thermotropic liquid crystalline polymer. In some aspects, the thermotropic liquid crystalline polymer is chosen such that a solidification temperature of the thermotropic liquid crystalline polymer is below an upper processing temperature of the thermoplastic polymer matrix. The filaments can be used for fused deposition manufacturing of a variety of parts, especially for the automotive and other industries.

Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for training and deploying machine-learning estimation networks in a communications system. One of the methods includes: processing first information with ground truth information to generate a first RF signal by altering the first information by channel impairment having at least one channel effect, using a receiver to process the first RF signal to generate second information, training a machine-learning estimation network based on a network architecture, the second information, and the ground truth information, receiving by the receiver a second RF signal transmitted through a communication channel including the at least one channel effect, inferring by the trained estimation network the receiver to estimate an offset of the second RF signal caused by the at least one channel effect, and correcting the offset of the RF signal with the estimated offset to obtain a recovered RF signal.

Abstract: Methods for inhibiting or treating viral infection in a subject infected with a vims of the arenaviridae family with a therapeutic agent combination: (a) arbidol and aripiprazole; (b) arbidol and amodiaquine; (c) arbidol and sertraline; (d) arbidol, iprazole, and amodiaquine; (e) arbidol, aripiprazole, and sertraline; or (f) aripiprazole and amodiaquine; or pharmaceutically acceptable salts thereof.

Abstract: Containment units, dry powder inhalers, delivery systems, and methods for the same are disclosed. Exemplary devices are configured to have inlets and outlets which are formed with the containment walls of a containment unit. Air jets formed by the configuration of inlet(s) and outlet(s) inside the containment unit create significant turbulence and deaggregate the powder. Delivery system components downstream of the containment unit may integrate the exiting aerosol plume with a low flow nasal cannula air stream for delivery to a subject.

Abstract: The present invention provides a method of treating depression disease in a treatment resistant patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, wherein the mucosal administration of the ketamine or dextromethorphan containing composition allows for the mucosal absorption of the composition eliminating the digestive tract of the patient for effecting a rapid acting antidepressant treatment of the treatment resistant patient. This method includes administering the composition to a patient's mucosal membrane of a respiratory tract, a genitourinary tract, an oral tract, or rectal tract of the patient. A pharmaceutically acceptable composition comprising ketamine or dextromethorphan and a vehicle is disclosed. A biomarker for identifying a depressive disease is set forth.

Abstract: A device and method that reduces impingement upon fragile airway structures and improves the performance and safety associated with endotracheal devices and related intubation procedures. The endotracheal device includes a lumen such that one end of the lumen includes an anterior beak that includes a distal tip of the anterior beak and a posterior beak having a distal tip of the posterior beak.

Abstract: The present disclosure relates to compositions and methods for enhanced engraftment of hematopoietic cells into the brain, and to therapeutic methods of treating central nervous system (CNS) diseases and disorders in subjects where replacing CNS pot macrophages (including microglia) and other tissue-resident macrophages with donor cells would be beneficial. In particular, the present disclosure relates to the use of a microglia depleting agent to enhance engraftment of hematopoietic-derived macrophages in the brain of a subject undergoing hematopoietic cell transplantation, to treat a subject suffering from a leukodystrophy and undergoing hematopoietic cell transplantation, to treat a subject suffering from a disease mediated by microglial dysfunction and undergoing hematopoietic cell transplantation, and to related methods. The present disclosure also relates to detection within cell populations of beMc? and microglia signatures.